

R E M A R K S

Claim 91 has been amended to include a SEQ ID number which was omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made.".

The undersigned hereby states that the computer readable form copy (CRF copy) of the Sequence Listing and the paper copy of the Sequence Listing for the above-captioned application, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 399632000420. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 5, 2001 By:


Bruce Grant
Registration No. 47,608

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7962
Facsimile: (858) 720-5125

MARKED-UP VERSION OF AMENDMENTS TO THE CLAIMS

In the Claims

91. (New) An isolated antigenic HLA-A3 binding peptide derived from a HIV-1 protein having the following formula:

Xaa₁Xaa₂Xaa₃Xaa₄Xaa₅Xaa₆Xaa₇Xaa₈Xaa₉Xaa₁₀

wherein Xaa₂ is Leu, Met, Ile, Val, Ser, or Thr, and Xaa₁₀ is Lys or Arg, and said isolated peptide provides lysis by cytotoxic T cells specific for a complex of said HLA molecule and said decapeptide. (SEQ ID NO. 104)